Bladder neoplasms and NF-κB: an unfathomed association.
Author | Jebaraj Walter, Charles Emmanuel |
Author | Durairajan, Sankari |
Author | Periyandavan, Kalaiselvi |
Author | Priya Doss C, George |
Author | Davis G, Dicky John |
Author | Vasanthi A, Hannah Rachel |
Author | Johnson, Thanka |
Author | Zayed, Hatem |
Available date | 2020-04-05T10:08:49Z |
Publication Date | 2020-03-01 |
Publication Name | Expert Review of Molecular Diagnostics |
Identifier | http://dx.doi.org/10.1080/14737159.2020.1743688 |
Citation | Charles Emmanuel Jebaraj Walter, Sankari Durairajan, Kalaiselvi Periyandavan, George Priya Doss C, Dicky John Davis G, Hannah Rachel Vasanthi A, Thanka Johnson & Hatem Zayed (2020) Bladder neoplasms and NF-κB: an unfathomed association, Expert Review of Molecular Diagnostics, DOI: 10.1080/14737159.2020.1743688 |
ISSN | 1473-7159 |
Abstract | Bladder cancer is the second most common genitourinary tract cancer and is often recurrent and/or chemoresistant after tumor resection. Cigarette smoking, exposure to aromatic amines, and chronic infection/inflammation are bladder cancer risk factors. NF-κB is a transcription factor that plays a critical role in normal physiology and bladder cancer. Bladder cancer patients have constitutively active NF-κB triggered by pro-inflammatory cytokines, chemokines, and hypoxia, augmenting carcinogenesis and progression.: NF-κB orchestrates protein interactions (PTEN, survivin, VEGF), regulation (CYLD, USP13) and gene expression (Trp 53) resulting in bladder cancer progression, recurrence and resistance to therapy. This review focuses on NF-κB in bladder inflammation, cancer and resistance to therapy.: NF-κB and bladder cancer necessitate further research to develop better diagnostic and treatment regimens that address progression, recurrence and resistance to therapy. NF-κB is a master regulator that can act with or on minimally one cancer hallmark gene or protein, leading to bladder cancer progression (Tp53, PTEN, VEGF, HMGB1, CYLD, USP13), recurrence (PCNA, BcL-2, JUN) and resistance to therapy (P-gp, twist, SETD6). Thus, an understanding of bladder cancer in relation to NF-κB will offer improved strategies and efficacious targeted therapies resulting in minimal progression, recurrence and resistance to therapy. |
Language | en |
Publisher | Taylor & Francis |
Subject | Bladder cancer NF-κB chemoresistance inflammation signal transduction |
Type | Article |
ESSN | 1744-8352 |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |
This item appears in the following Collection(s)
-
Biomedical Sciences [697 items ]